ELITE PHARMACEUTICALS INC /NV/ - 10-Q Filing

Elite Pharmaceuticals Inc. reports Q2 2027 financial results with significant revenue segmentation across Abbreviated New Drug Applications and licensing.

SEC EDGAR ·

Tickers: $ELTP

Read the full article at SEC EDGAR

More Regulatory news